Advertisement

Search Results

Advertisement



Your search for Matthew D. Galsky, MD matches 7 pages

Showing 1 - 7


bladder cancer

Metastatic Urothelial Carcinoma: A Model Malignancy for Immune ­Checkpoint Blockade

Platinum-based combination chemotherapy became a mainstay of first-line treatment for metastatic urothelial cancer in the 1980s. With combination platinum-based regimens, 40% to 50% of patients achieve an objective response to treatment. However, aside from approximately 5% to 10% of patients who...

bladder cancer

Anti–PD-1 Contenders in Advanced Urothelial Cancer

Immunotherapy with anti–PD-1 (programmed cell death protein 1) and anti–PD-L1 (programmed cell death ligand 1) agents continues to advance in metastatic urothelial cancer, with positive showings in two clinical trials presented at the 2016 European Society for Medical Oncology (ESMO) Congress. The...

Expert Point of View: Highlights of Bladder Cancer Research Include Novel Agents and New Approach to Identifying Biomarkers

Although bladder cancer is among the most chemosensitive of the solid tumors, and a large proportion of patients will achieve objective tumor regressions on first-line therapy with conventional chemotherapeutic regimens, response durations are relatively short and outcomes with existing second-line ...

Five Organizations Awarded 2015 International Innovation Grants to Improve Cancer Care in Low- and Middle-Income Countries

The Conquer Cancer Foundation of ASCO has announced the five recipients of the 2015 International Innovation Grant. This grant supports novel and innovative projects that may improve diagnosis, prevention, and treatment of cancer in low- and middle-income countries. For 2015, the 1-year grants of...

bladder cancer

Adjuvant Chemotherapy Favored in Locally Advanced Bladder Cancer Not Treated With Neoadjuvant Therapy

A large observational study presented at the 2015 Genitourinary Cancers Symposium in Orlando, Florida, found that adjuvant chemotherapy extended the likelihood of survival in locally advanced bladder cancer compared with observation alone.1 Using three different approaches to propensity scores...

issues in oncology

Poor Geographic Accessibility of Advanced Cancer Clinical Trial Sites

It is estimated that approximately 2% to 7% of U.S. adult patients with cancer participate in clinical trials, and poor geographic accessibility of clinical trial sites contributes to this low participation. In a study reported in JAMA Internal Medicine, Galsky et al found that approximately 40% to ...

Suboptimal Adverse Event Reporting in Cancer Clinical Trial Publications

In a study reported in the Journal of Clinical Oncology, Sivendran et al assessed the degree to which publication of phase III trials in oncology conformed with CONSORT (Consolidated Standards of Reporting Trials) recommendations for reporting adverse events. They found that adverse event...

Advertisement

Advertisement



Advertisement